RXRX Stock News & Catalysts – Recursion Pharmaceuticals

FEATURED

Portal Innovations and Altitude Lab Partner to Strengthen Utah’s Life Sciences Startup Ecosystem

Altitude Lab to serve as anchor member of Portal at Woodbine Labs, bringing accelerator programming and emerging life sciences companies into a new 30,000 square foot innovation hub in Salt Lake City Portal

Summary

Nov 5, 2026, 11:15 AM ·Business Wire

RECENT

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in larger, higher-risk

Nov 2, 2026, 4:30 PM ·Globe Newswire

New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps

Updated TUPELO results featured in a Presidential Plenary at CGA-IGC: Lisa Boardman, M.D., Professor of Medicine at Mayo Clinic, presented updated findings from the Phase 1b/2 TUPELO trial in familial adenomatous

Nov 2, 2026, 4:25 PM ·Globe Newswire

Recursion Appoints Fred Hassan as Chair of the Board

Salt Lake City, UT, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has

Nov 2, 2026, 4:05 PM ·Globe Newswire

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMTThird quarter 2026 results will

Oct 26, 2026, 4:05 PM ·Globe Newswire

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding

Oct 15, 2026, 8:45 AM ·Globe Newswire

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Oct 15, 2026, 8:30 AM ·Globe Newswire

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in

Oct 15, 2026, 8:22 AM ·Globe Newswire

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which

Sep 21, 2026, 9:14 AM ·Business Wire

The Market Just Told You Which Layer Of AI Biology It Is Paying For

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry’s data

Sep 3, 2026, 2:10 PM ·Globe Newswire

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for

Aug 5, 2026, 6:30 AM ·Globe Newswire

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following

Aug 4, 2026, 8:00 AM ·Globe Newswire

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation

Jul 31, 2026, 4:30 PM ·Globe Newswire

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives,

Jul 29, 2026, 8:30 AM ·Globe Newswire

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

Issued on behalf of MindWalk Holdings Corp. (NASDAQ:HYFT)AUSTIN, Texas, July 24, 2026 /CNW/ -- American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the

Jul 24, 2026, 9:10 AM ·PRNewswire

Recursion Pharmaceuticals, Inc. RXRX · News